Abstract
ABSTRACT AT THE START of the second year after initial clinical use of gene replacement therapy, the patient is doing exceptionally well, says R. Michael Blaese, MD, National Cancer Institute who, with W. French Anderson, MD, National Heart, Lung, and Blood Institute, is one of the principal National Institutes of Health (NIH) clinicians involved in the study (JAMA. 1991; 265:2311-2312).The patient, a 5-year-old girl, has adenosine deaminase (ADA) deficiency, a rare genetic disorder that paralyzes the immune system. On September 14,1990, at the NIH in Bethesda, Md, she received the first of eight infusions of her lymphocytes, cocultivated in the presence of a retroviral vector carrying the missing ADA gene. Some percentage of the lymphocytes pick up the gene and the gene-corrected lymphocytes are reinfused back into the patient.For 2 years before the patient became the first to receive gene replacement treatment, she had been receiving enzyme replacement with
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
